Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to support (a) investigator-led and (b) commercially-sponsored clinical trials in blood cancer research.
Answered by Andrew Gwynne
The Department-funded National Institute of Health and Care Research (NIHR) funds research and research infrastructure which supports patients and the public to participate in high-quality research, including clinical research on blood cancer.
NIHR infrastructure provides world-class research expertise, specialist facilities, a research delivery workforce, and support services, which all help to support and deliver research across the National Health Service and the wider health and care system.
The Department is committed to implementing the recommendations of Lord O'Shaughnessy’s review into commercial clinical trials, making sure the United Kingdom is one of the best places in the world to conduct cutting-edge clinical research, including research into cancer.
The Department spends £1.5 billion per year on research through the NIHR. NIHR research expenditure for all cancers was over £121.8 million for 2022/23, with more spent on cancer than any other disease group.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will take steps to hold discussions with his counterparts in the devolved Administrations on co-ordinating national cancer registries in their (a) collection, (b) analysis and (c) reporting of blood cancer data.
Answered by Andrew Gwynne
There are no current plans to hold discussions with the devolved administrations on co-ordinating national cancer registries. The National Disease Registration Service (NDRS), which includes the National Cancer Registration and Analysis Service, is a member of the United Kingdom and Ireland Association of Cancer Registries (UKIACR). The UKIACR has interests in all aspects of cancer registration, both in its methodology and in its application, to the collection, analysis, and publication of population-based data on the incidence, mortality, and survivability from cancer, and in the use of this data for research aimed at controlling cancer in the population. More details are available at the following link:
https://ukiacr.org/about/ukiacr-constitution
Staff from the NDRS attend quarterly UKIACR executive meetings, where collaboration and standardisation, where possible, of the collection and reporting of cancer data is discussed. NDRS analysts also attend quarterly meetings with UKIACR analysts, where detailed discussions are held to ascertain any differences in the reporting of cancer data, and how these can be made analogous. Annual performance indicators, including key performance indicators for haematology, are available at the following link:
England and Wales use the same cancer registration information and communication technology environment, and contracts are held between England, Wales, and Scotland, respectively, to provide the mechanisms to collect and store radiotherapy data.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of participation in clinical trials for blood cancer; and whether he plans to take steps to increase the level of participation among underrepresented groups.
Answered by Andrew Gwynne
No such assessment has been made. The Department-funded National Institute of Health and Care Research (NIHR) funds research and research infrastructure which supports patients and the public to participate in high-quality research. The NIHR supported the opening of 171 studies on blood cancer and the recruitment of 7,939 participants between 2021/22 and 2023/24, indicating a consistent level of participation.
The Department is committed to implementing the recommendations of Lord O'Shaughnessy’s review into commercial clinical trials, maximising the United Kingdom’s potential to lead the world in clinical trials, and ensuring that innovative, lifesaving treatments are accessible to National Health Service patients. Our aim is to ensure all patients, including those in underrepresented groups, are empowered to directly and proactively explore research opportunities.
The NIHR provides an online service called Be Part of Research, which promotes participation in health and social care research by allowing users to search for relevant studies and register their interest. This can also be accessed through the NHS App. This makes it easier for people to find and take part in health and care research that is relevant to them.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will take steps to help ensure blood cancer is routinely included as a distinct category when reporting on (a) prevalence, (b) healthcare utilisation and (c) other appropriate benchmarks.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The National Disease Registration Service, through the National Cancer Registration and Analysis Services (NCRAS), collects information on how many people in England have cancer. Blood cancer is included as a distinct category, labelled haematological neoplasms. The National Disease Registration Service’s website also shows the number of people treated for different tumour types by treatment type, as well as survival rates, mortality rates, and data on urgent suspected cancer referrals. This information is available at the following link:
https://www.cancerdata.nhs.uk/
All cases of cancer diagnosed and treated in the National Health Service in England are registered by the NCRAS. This creates a clinically rich data resource that is used to measure diagnosis, treatment, and outcomes for patients diagnosed with cancer. The data held by the NCRAS supports service provision and commissioning in the NHS, clinical audits, and public health and epidemiological research, all of which contribute to improved outcomes for those diagnosed with cancer.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) help improve patient understanding of self-monitoring of blood cancer and (b) increase funding for (i) sign-posting and referrals into charity support services and (ii) other resources for patient advocacy.
Answered by Andrew Gwynne
NHS England is committed to ensuring that all cancer patients are offered Holistic Needs Assessment and Personalised Care and Support Planning, ensuring care is focused on what matters most to each person. This is being delivered in line with the NHS Comprehensive Model for Personalised Care, empowering people to manage their care and the impact of their cancer, and maximise the potential of digital and community-based support.
Health and wellbeing information and support is provided from diagnosis onwards and includes access to NHS Talking Therapy services for anxiety and depression. This is alongside wider work to improve psychosocial support for people affected by cancer, such as through local partnerships with cancer support charities.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the report by Lord Darzi entitled Independent investigation of the NHS in England, published on 12 September 2024, what steps he plans to take to improve the quality of the NHS equipment referenced in that report.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Professor Lord Darzi highlights that the National Health Service has been starved of capital, with outdated scanners, too little automation, and that the NHS is failing to enter the digital era. The findings provide a diagnosis of the challenges facing the NHS which will inform the solutions, including the 10-year plan to reform the NHS.
Digital transformation and technology are critical to the future of the NHS. We are committed to providing the NHS with the latest technology and replacing outdated equipment to catch cancer and other conditions earlier, thereby saving lives.
As part of this, we are progressing our commitment to double the number of magnetic resonance imaging and computed tomography scanners to address the challenges in diagnostic waiting times, accelerate cancer diagnosis, and build an NHS fit for the future. We will harness the power of technologies like artificial intelligence to transform the speed and accuracy of diagnostic services, saving potentially thousands of lives.
The Frontline Digitisation programme is working to improve digital maturity across the NHS, prioritising hardware, connectivity, and electronic patient record systems. National support is in place for trusts to procure and implement electronic patient records.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking improve the disparities experienced by those from (a) ethnic minorities, (b) deprived backgrounds and (c) geographically remote locations in accessing a timely diagnosis of blood cancer.
Answered by Andrew Gwynne
Making improvements across different cancer types is critical to reducing disparities in cancer survival. Early cancer diagnosis is also a specific priority within the National Health Service’s wider Core20Plus5 approach to reducing healthcare inequalities.
We recognise there are particular challenges for a number of different populations, particularly for people living in the most deprived areas of the country. As part of our wider strategy on early diagnosis, we are directly targeting our activity at areas we know will make a difference.
The NHS’s Help Us, Help You cancer campaigns increase awareness of cancer symptoms, address barriers, and encourage people to get checked. Some campaigns focus on specific symptoms while others focus on fear as a barrier to help-seeking, which is relevant across all cancer types. The key target audience for these campaigns are people aged 50 year old and over living in more disadvantaged areas, as well as groups more likely to experience health inequalities, such as black and South Asian people.
NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of local communities are met, including providing support for travel.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the adequacy of funding allocated to cancer research by his Department; and if he will have discussions with the Chancellor of the Exchequer on increasing such funding.
Answered by Andrew Gwynne
Cancer remains a priority area for the Government, and £1.5 billion has been invested on health research through the National Institute for Health and Care Research (NIHR). The NIHR’s research expenditure for all cancers was over £121.8 million for 2022/23, with more spent on cancer than any other disease group. The overall budget for research investment is agreed with the Treasury at the outset of each Spending Review period, and the Department regularly engages with the Chancellor of the Exchequer about a range of issues.
Our investments in cancer are pivotal to informing efforts to improve cancer prevention, treatment, and care.
The NIHR continues to encourage and welcome applications for research into any aspect of human health, including all cancer types. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients, health and care services, value for money, and scientific quality.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that (a) pancreatic cancer and (b) cystic fibrosis patients have access to Creon.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT), including Creon, used in the treatment of cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe, and have been caused by the limited availability of raw ingredients and manufacturing capacity constraints in producing the volumes needed to meet demand. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.
We have issued comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review, and updates will be made as necessary. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules to limit prescriptions to one months’ supply, to allow demand management.
We understand how frustrating and distressing medicine supply issues can be. While we can’t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and to help mitigate risks to patients.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he is taking steps to (a) raise awareness of and (b) help increase stem cell donation.
Answered by Andrew Gwynne
The Department’s Stem Cell Programme is providing £2.4 million of funding for the period 2022 to 2025. The programme is being delivered by NHS Blood and Transplant (NHSBT), and Anthony Nolan. It aims to enhance the resilience of the United Kingdom’s stem cell supply by strategically recruiting donors, particularly those most likely to donate, and to address health disparities through targeted campaigns, with a focus on ethnic minority communities. By increasing the pool of potential donors, the programme seeks to improve the availability of matches in the UK, ultimately reducing waiting times for patients in need of stem cell treatment.
The UK aligned registry has over 2 million potential stem cell donors registered. NHSBT and Anthony Nolan are raising awareness of the importance of stem cell donation and increasing the number of donors on the register through a range of methods including partnering with community organisations, working with volunteer student groups, and engaging with active blood, plasma, and platelet donors.